Confo Therapeutics
Rob Scott, MD, a trained physician, has held leadership positions in global pharmaceutical companies for thirty years. He has managed drug development teams responsible for highly successful pharmaceutical brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. His most recent position was Chief Medical Officer and Head of Development at AbbVie. Before that, he was Vice President, Global Development TA Head and Head of Development Design Center at Amgen. From 2012 - 2016 he was a member of the US Food and Drug Administration’s Cardiovascular and Renal Drug Advisory Committee where he built strong relationships with senior FDA staff. Before Amgen, he held several leadership positions with emerging pharmaceutical and biotech companies.
Dr. Scott is a graduate from the University of Cape Town, South Africa and started his career at Janssen as a Medical Advisor. He has been a board member of TransCelerate and a member of the PhRMA R&D Leadership Forum.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.